Pharmaceutical Business review

Aegis peptide analogs receive US patent

GLP-1 peptide analogs are suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes or injection.

Aegis’ patented drug delivery and drug formulation technologies include Intravail drug delivery technology which enables the non-invasive delivery of a protein, peptide and non-peptide drugs.

The ProTek technology is used for aqueous or lyophilized dosage forms to maintain product integrity and reduce unwanted immunogenicity of protein and peptide therapeutics.